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Introduction 
Nearly 36 million people worldwide are living with dementia, and as the population ages, this 
number is expected to more than triple by 2050. The countries with the largest number of people 
with dementia are China (5.4 million), Japan (4.3 million), the United States (3.9 million), India (3.7 
million), Germany (1.5 million), Russia (1.2 million), France (1.1 million), Italy (1.1 million) and 
Brazil (1.0 million). Dementia has become a prominent social issue [1, 2]. Alzheimer’s disease (AD), 
the most common cause of dementia, is characterized by extracellular deposits of amyloid beta (Aβ) 
protein and intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated tau. 
Acetylcholinesterase inhibitors (donepezil, galantamine and rivastigmine) and an 
N-methyl-d-aspartate (NMDA) receptor antagonist (memantine) are currently the only approved 
drugs for the treatment of AD [3]. However, because these drugs do not target Aβ and 
hyperphosphorylated tau, it is difficult to prevent, halt, or reverse the disease [4]. 
In spite of efforts to discover drugs targeting Aβ, no truly effective therapy has been developed to 
date [5]. Solanezumab and bapineuzumab are one of the most notable immunotherapeutic agents 
targeting Aβ. In phase 3 clinical trials, the immunotherapies had no effect on behavioral tests of 
mild- to moderate-AD patients [6]. The results of these clinical trials indicate that reversing the 
degeneration of neuronal networks after the progression of AD is difficult. We propose that it is 
important for new anti-AD drugs to reverse the degeneration of neuronal networks after the 
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appearance of symptoms. 
From this point of view, we are investigating drugs used in Japanese traditional medicine (called 
Kampo), focusing on kamikihito (KKT). KKT is an herbal drug known for its effectiveness in 
treating insomnia, loss of appetite, amnesia, and depression. We previously reported the effect of 
KKT in the 5XFAD mouse model of AD [7]. 5XFAD mice exhibit increased Aβ production, Aβ 
plaques, and gliosis at 2 months of age and synapse loss and memory impairment at 4 months of age 
[8]. Therefore, 5XFAD mice are considered to be a model of AD after the appearance of symptoms. 
Our previous study showed that the administration of KKT to 5XFAD mice (4-7 months old) for 15 
days improves memory impairment and reverses the degeneration of cortical axons and presynaptic 
terminals. These effects could be beneficial for AD patients, but the mechanism underlying the 
effects of KKT remains unknown. The aim of the present study is to investigate the mechanism by 
which KKT reverses progressive axon degeneration. 
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Chapter 1 
Kamikihito reverses amyloid-β-induced progression of 
tau phosphorylation and axonal atrophy. 
 
1.1  Introduction 
Amyloid beta (Aβ) is widely believed to play a crucial role in AD pathology, and there have been 
numerous attempts to discover drugs targeting Aβ. However, recent clinical trials have wholly faced 
failures. In the decade from 2002 to 2012, 244 compounds were attempted in 413 clinical trials for 
AD, and the only one compound (memantine) was approved for marketing [9, 10]. Anti-Aβ therapies, 
for example anti-Aβ antibody and γ-secretase inhibitor, were attempted the most in AD clinical trials 
(70 compounds in 146 trials). Most recently in two phase 3 trials, bapineuzumab, a humanized 
monoclonal antibody that recognizes the N-terminus of Aβ and binds both soluble and aggregated 
Aβ, failed to improve cognitive dysfunction in patients with mild- to moderate AD [11]. In two 
additional phase 3 trials, solanezumab, a humanized monoclonal antibody to Aβ (16–24) that 
preferentially binds soluble Aβ, also failed to improve cognitive dysfunction [12]. Under the 
unfortunate situation, it is no wonder to think that targeting Aβ is not sufficient for radical cure of 
AD [13, 14].  
Neurofibrillary tangles, which are composed of hyperphosphorylated tau, also play an important 
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role in pathologies of AD. Therapeutic approaches targeting hyperphosphorylated tau, such as tau 
aggregation inhibitors drugs, are currently under investigation, but such efforts are on a very small 
scale. It was reported that tau aggregation precedes Aβ deposits and is already progressed when AD 
is diagnosed. Therefore it is important to reverse the tau phosphorylation, not to inhibit, for treatment 
AD targeting tau.  
We investigated the effect of KKT to tau phosphorylation and demonstrated that KKT 
post-treatment reversed the Aβ-induced increase in tau phosphorylation via protein phosphatase 2A 
(PP2A) activation [15].  
 
1.2 Materials and Methods 
All experiments were performed in accordance with the Guidelines for the Care and Use of 
Laboratory Animals of the University of Toyama. 
 
1.2.1. Preparation of KKT extract 
KKT is composed of 14 crude drugs: Ginseng Radix (Panax ginseng C.A. Meyer), Polygalae 
Radix (Polygalae tenuifolia Willd.), Astragali Radix (Astragalus membranaceus Bunge), Zizyphi 
Fructus (Zizyphus jujube Mill. var. inermis Rehd.), Zizyphi Spinosi Semen (Z. jujube Mill. 
var. spinosa), Angelicae Radix (Angelica acutiloba Kitagawa), Glycyrrhizae Radix (Glycyrrhiza 
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uralensis Fisch), Atractylodis Rhizoma (Atractylodes japonica Koidzumi ex Kitamura), Zingiberis 
Rhizoma (Zingiber officinale Roscoe), Poria (Poria cocos Wolf), Saussureae Radix (Saussurea 
lappa Clarke), Longanae Arillus (Euphoria longana Lam.), Bupleuri Radix (Bupleurum falcatum 
Linne), and Gardeniae Fructus (Gardenia jasminoides Ellis) at a ratio of 
3 : 1.5 : 2: 1.5 : 3: 2 : 1 : 3 : 1 : 3 : 1 : 3 : 3 : 3, respectively. All crude drugs were purchased from 
Tochimoto Tenkaido (Osaka, Japan). The mixture of crude drugs (100 g) was extracted with water 
(500 mL) at 100°C for 50 min, evaporated under reduced pressure, and freeze-dried to obtain a 
powder extract (12.3 g). 
 
1.2.2. Primary culture 
Embryos were removed from a pregnant ddY mouse (Japan SLC, Shizuoka, Japan) at 14 days of 
gestation. The cerebral cortices were dissected, and the dura mater was removed. The tissues were 
minced, dissociated and cultured with Neurobasal medium (Gibco BRL, Rockville, MD, USA) 
containing 12% horse serum, 0.6% D-glucose and 2 mM L-glutamine. Cells were grown in 8-well 
chamber slides (Falcon, Franklin Lakes, NJ, USA) or 10-cm dishes coated with 5 µg/ml 
poly-D-lysine at 37°C in a humidified incubator with 10% CO2. On the next day of culture, the 
medium was replaced with fresh Neurobasal medium containing 2% B-27 supplement rather than 
horse serum. 
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1.2.3. Aβ-induced axonal atrophy 
Mouse cortical neurons (E14) were cultured in 8-well chamber slides (Falcon, Franklin Lakes, NJ, 
USA) at a density of 1.45 × 104 cells/cm2 for 3 days. To induce axon atrophy, the cells were treated 
with Aβ (25–35) (10 µM) (Sigma-Aldrich, St Louis, MO, USA). The Aβ (25-35), an active fragment 
of Aβ, was previously incubated for 4 days at 37°C to induce aggregation. In experiments involving 
pre-treatment, KKT (10 µg/ml), kenpaullon (KPL, 1 µM; an inhibitor of glycogen synthase 
kinase-3β: GSK-3β) or vehicle was administered to the cells, and Aβ (25-35) was added to the cells 
1 h later. At 24 h after incubation with Aβ, the medium was replaced with Aβ (25-35)-free medium, 
and the drug treatments were continued for an additional 72 h. In experiments involving 
post-treatment, cells were incubated with Aβ (25-35) (10 µM) for 24 h. The medium was then 
replaced to remove Aβ (25-35). The replacement medium contained KKT (10 µg/ml), KPL (1 µM) 
or vehicle. After drug treatment for 72 h, the cells were fixed with 4% paraformaldehyde and 
immunostained axons with a monoclonal antibody against phosphorylated NF-H (pNF-H, dilution 
1 : 500, Sternberger Monoclonals, Luthervulle, MD, USA) and neuronal cell bodies with a 
polyclonal antibody against MAP 2a and 2b (MAP2, dilution 1 : 500, Chemicon, Temecula, CA, 
USA). Secondary antibodies were Alexa Fluor 488-conjugated goat anti-mouse IgG (dilution 
1 : 300) and Alexa Fluor 568-conjugated goat anti-rabbit IgG (dilution 1 : 300) (Molecular Probes, 
Eugene, OR, USA). Fluorescent images were detected by a fluorescence microscope system 
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(BX-61/DP70, Olympus, Tokyo, Japan). The lengths of axons were measured using the Neurocyte 
image analyzer (Kurabo, Osaka, Japan), which automatically traced and measured neurite lengths 
without measuring cell bodies. The total length of the axons was divided by the number of cells in an 
identical area to calculate the average length of axon per neuron. 
 
1.2.4. Aβ-induced tau phosphorylation 
Mouse cortical neurons (E14) were cultured in 8-well chamber slides at a density of 1.45 × 104 
cells/cm2 for 3 days. For pre-treatment experiments, KKT (10 µg/ml), KPL (1 µM) or vehicle was 
administered to the cells, and Aβ (25-35) (10 µM) was added 1 h later. At 4 h or 72 h after incubation 
with Aβ, the cells were fixed. For post-treatment experiments, cells were treated with Aβ (25-35) 
(10 µM) for 24 h. Then, the medium was replaced with medium lacking Aβ (25-35). KKT (10 µg/ml), 
KPL (1 µM) or vehicle was included in the replacement medium. At 72 h after drug treatment, the 
cells were fixed and immunostained with a monoclonal antibody against paired helical filament tau 
(PHF-tau, AT-8 clone, dilution 1: 200, Thermo Scientific, Rockford, IL, USA). Alexa Fluor 
488-conjugated goat anti-mouse IgG (dilution 1: 300) was used as the secondary antibody. Images 
were captured using a fluorescence microscope system (BX-61/DP70, Olympus). The level of tau 
phosphorylation was measured as the fluorescence intensity in the cell body of each neuron using a 
CS analyzer (ATTO, Tokyo, Japan). 
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1.2.5. PP2A activity assay 
Mouse cortical neurons (E14) were cultured in a 10-cm-dish at a density of 8.67 × 104 cells/cm2 
for 3 days. KKT (10 µg/ml) or vehicle was administered to the cells, and Aβ (25–35)(10 µM) was 
added 1 h later. At 72 hours after incubation with Aβ, the cells were harvested and suspended in 
phosphate storage buffer [2 mM EGTA, 5 mM EDTA, 0.5 mM PMSF, 150 mM NaCl, 50 mM 
Tris-HCl (pH 7.4), 1% Triton X-100 and protease inhibitor cocktail (1:200)]. The cell lysates were 
sonicated and centrifuged at 16,000 ×g for 10 min, and the supernatants were used for the PP2A 
activity assay. PP2A activity was measured using a serine/threonine phosphatase assay system 
(V2460, Promega, Madison, WI, USA) according to the manufacturer’s protocol. The cell lysates 
were passed twice through Sephadex® G-25 Spin Columns to remove endogenous free phosphate. 
The protein concentration was determined using the Pierce® 660 nm Protein Assay. PP2A reaction 
buffer (50 mM imidazole, pH 7.2, 0.2 mM EGTA, 0.02% β-mercaptoethanol and 0.1 mg/ml bovine 
serum albumin) and 1 mM phosphopeptide were prepared in a 96-well plate. The enzyme reaction 
was started by adding 2.5 µg of the protein lysate to each well, and the mixture was incubated for 
30 min at 33°C. The reaction was stopped by the addition of 50 µl of molybdate dye-additive 
mixture, and the plate was incubated at room temperature for 15 min. Phosphate release from the 
substrate was detected by measuring the absorbance of the molybdate-malachite green-phosphate 
complex at 630 nm. 
10 
 
1.2.6. Animals 
Transgenic mice (5XFAD) [8] were obtained from Jackson laboratory (Bar Harbor, ME, USA). To 
investigate the effect of KKT on 5XFAD mice, the study used hemizygous 5XFAD mice (female, 
9–11 months) and non-transgenic wild-type mice (female, 9–10 months). All mice were housed with 
free access to food and water and kept in a controlled environment (22 ± 2°C, 50 ± 5% humidity, 
12 h light cycle starting at 7:00 am). 
KKT was dissolved in physiological saline. KKT (500 mg/kg/day) or vehicle solution was 
intragastrically administered once a day for 15 days. On the 16th day, the mice were sacrificed, and 
the cerebral cortex was isolated and homogenized in phosphate storage buffer for the PP2A activity 
assay.  
 
1.2.7. GSK-3β activity assay 
Mouse cortical neurons (E14) were cultured in 8-well chamber slides at a density of 1.45 × 104 
cells/cm2 for 3 days. KKT (10 µg/ml) or vehicle was administered to the cells, and Aβ (25–35) 
(10 µM) was added 1 h later. At 4 h after incubation with Aβ, the cells were fixed with 4% 
paraformaldehyde and immunostained with a monoclonal antibody against phosphorylated GSK-3β 
at Tyr-216 (pY216, dilution 1: 200, BD Biosciences, Franklin Lakes, NJ, USA) as a marker of 
activated GSK-3β and a polyclonal antibody against GSK-3β (dilution 1: 500, Santa Cruz 
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Biotechnology, Santa Cruz, CA, USA) as a marker of total GSK-3β. Alexa Fluor 488-conjugated 
goat anti-mouse IgG (dilution 1 : 300) and Alexa Fluor 568-conjugated goat anti-rabbit IgG (dilution 
1 : 300) were used as secondary antibodies. Images were captured using a fluorescence microscope 
system (BX-61/DP70, Olympus). Expression of phosphorylated GSK-3β and total GSK-3β was 
measured by determining the fluorescence intensity in the cell body of each neuron using a CS 
analyzer (ATTO). The ratio of GSK-3β (pY216) to GSK-3β (total) was calculated.  
 
1.2.8. Statistical analysis 
Statistical comparisons were performed through a One-way analysis of variance (ANOVA) with 
post hoc Dunnett's test or Bonferroni's Multiple Comparison Test using GraphPad Prism 5 
(GraphPad Software, La Jolla, CA, USA). p < 0.05 was considered significant. The data are 
presented as the means ± SE. 
 
1.3. Results 
 
1.3.1. KKT decreases Aβ (25-35)-induced phosphorylation of tau. 
We first focused on the effectiveness of KKT against Aβ (25-35)-induced phosphorylation of tau. 
Full-length Aβ (1-42) and its active fragment Aβ (25-35) have been reported to induce 
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phosphorylation of tau [16, 17]. Phosphorylation of tau leads to axon transport deficits, synaptic loss 
and mitochondrial dysfunction, resulting in axonal dysfunction [18-20]. Among the various kinases 
involved in phosphorylation of tau, GSK-3β plays a critical role in AD pathology [21]. We therefore 
investigated the effect of KKT (10 µg/ml) and KPL (inhibitor of GSK-3β; Ki = 0.23 µM) (1 µM) on 
Aβ (25-35)-induced phosphorylation of tau. Drugs were administered pre- or post-treatment with Aβ 
(25-35).  
As shown in Figure 1A, treatment of cortical neurons with Aβ (25-35) for 4 h resulted in a 
3.7-fold increase in phosphorylation of tau compared with the control. However, the phosphorylation 
of tau was attenuated to 2.6-fold by 1 h of pre-treatment with KKT (10 µg/ml). With KPL 
pre-treatment, phosphorylation of tau was remarkably prevented with 1.4-fold (Figure 1A). Tau 
remained phosphorylated at 72 h after Aβ (25-35) treatment, although the degree of phosphorylation 
was lower than at 4 h after treatment (Figure 1B). Phosphorylation of tau in the late phase was 
remarkably prevented by pre-treatment with KKT, but pre-treatment with KPL resulted in only a 
slight attenuation of tau phosphorylation. 
We next investigated the effects of post-treatment with KKT (10 µg/ml) and KPL (1 µM) on Aβ 
(25-35)-induced phosphorylation of tau (Figure 2). We added Aβ (25-35) to the cells for 24 h, and 
the cells were incubated with each drug for the next 72 h without Aβ (25-35). KPL no longer 
affected the Aβ-induced phosphorylation of tau under these conditions, whereas KKT post-treatment 
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significantly inhibited the phosphorylation of tau. 
These results suggest that KKT reduces the phosphorylation of tau at both early and late phases 
and that increased tau phosphorylation can be reversed by KKT. In contrast, KPL may inhibit the 
phosphorylation of tau only in the early phase.  
 
1.3.2. KKT reverses Aβ (25-35)-induced axonal atrophy 
Figure 1 shows that KKT remarkably reduced the phosphorylation of tau in the late phases (Figure 
1B), and KPL prevented the phosphorylation of tau more completely in the early phases (Figure 1A). 
Inhibition of tau phosphorylation by KPL no longer occurred when phosphorylation had already 
progressed (Figure 2). Because it is known that Aβ induces axonal atrophy through phosphorylation 
of tau, we investigated the effects of KKT and KPL on Aβ (25-35)-induced axonal atrophy. 
Treatment of cortical neurons with Aβ (25-35) (10 µM) for 24 h significantly decreased the axonal 
density (Figure 3A), which did not recover even 72 h after the removal of Aβ (25-35) (Figure 3B). In 
the pre-treatment protocol, administration of KKT (10 µg/ml) and KPL (1 µM) significantly 
inhibited Aβ (25-35)-induced axonal atrophy (Figure 3A). The protection of axonal atrophy was 
equivalent in neurons that were pre-treated with KKT or with KPL. In contrast, in the post-treatment 
protocol, only administration of KKT reversed Aβ (25-35)-induced axonal atrophy (Figure 3B). 
These results suggest that KKT, but not KPL, increases axonal density even after axonal atrophy has 
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already progressed. 
 
1.3.3. KKT reverses the Aβ-induced decrease in PP2A activity 
KKT remarkably reduced the phosphorylation of tau in the late phase (Figure 1B). To explain the 
long-lasting inhibitory effect of KKT on the phosphorylation of tau, we proposed that KKT may play 
a role in the dephosphorylation of tau. It was previously reported that Aβ increases the 
phosphorylation of tau by decreasing PP2A activity [22]; we therefore investigated the effect of 
KKT on PP2A activity under Aβ (25-35) treatment. KKT (10 µg/ml) was added to the cells, and Aβ 
(25-35) (10 µM) was added 1 h later. PP2A activity was measured 72 h after Aβ addition. As shown 
in Figure 4A, Aβ treatment decreased PP2A activity to 79.6 % compared with the control group. 
However, pre-treatment with KKT completely prevented the decrease in PP2A activity (Figure 4A).  
PP2A activity was also measured in vivo. KKT (500 mg/kg/day) was administered orally to the 
5XFAD mice, and cerebral cortex lysates were prepared for measurement of PP2A activity. Our 
previous data showed that KKT administration for 15 days completely restored memory impairment 
in 5XFAD mice [7]. In the present experiment, we further confirmed that memory was improved by 
KKT treatment (data not shown). Vehicle-treated 5XFAD mice showed a significant decrease in 
PP2A activity compared with wild-type mice. However, KKT treatment of 5XFAD mice 
significantly increased PP2A activity compared with vehicle treatment (Figure 4B). These results 
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demonstrate that KKT enhances the activity of PP2A under Aβ (25-35)-induced down-regulation of 
PP2A activity.  
 
1.3.4. KKT has no effect on GSK-3β activity 
Figures 1 and 2 show that KKT inhibits the Aβ (25-35)-induced phosphorylation of tau in both the 
early and late phases. However, the effect of KKT in the early phase was lower than that of KPL. 
Because the effects of KKT and KPL were different, we next investigated whether KKT was also an 
inhibitor of GSK-3β or not. GSK-3β activity was shown to be regulated by phosphorylation at 
specific residues; for example, phosphorylation of Ser9 and Ser389 inhibited its kinase activity, 
whereas phosphorylation at Tyr216 was required for its activation [23]. In this experiment, we 
measured the ratio of GSK-3β (pY216) to GSK-3β (total) to evaluate the level of GSK-3β activation. 
As shown in Figure 5, Aβ (25-35) (10 µM) treatment for 4 h significantly increased the amount of 
phosphorylated GSK-3β (Tyr216). However, pre-treatment with KKT (10 µg/ml) had no effect on 
this increase (Figure 5). These results suggest that KKT may not be involved in the regulation of 
GSK-3β activity.  
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1.4. Discussion 
Senile plaques and neurofibrillary tangles are two hallmark pathologies of AD. Senile plaques 
contain extracellular deposits of fibrillar Aβ, and neurofibrillary tangles are composed of 
hyperphosphorylated tau. It has been reported that Aβ induces phosphorylation of tau [16, 17] and 
that the phosphorylation of tau leads to axon transport deficits, synaptic loss, and mitochondrial 
dysfunction [19–20]. These disturbances eventually lead to axonal degeneration and neuronal death. 
Consequently, therapeutic approaches targeting tau have been growing steadily in recent years. For 
example, 2-methyl-5-(3-4-[(S)-methylsulfinyl]phenyl-1-benzofuran-5-yl)-1,3,4-oxadiazole (MMBO) 
and NP12 have been reported to decrease tau phosphorylation and reverse cognitive deficits in AD 
mouse models, which are novel GSK-3 inhibitors [24, 25]. In patients with mild to moderate AD, 
methylene blue (a tau aggregation inhibitor) is effective in treating cognitive deficits [26]. Phase II 
clinical trials of NP12 (tideglusib) and phase III clinical trials of LMTX, a derivative of methylene 
blue, are ongoing. 
In this study, we investigate the mechanism underlying the effect of KKT. KKT reversed memory 
impairment in 5XFAD mice in our previous study [7], and here we demonstrate three properties of 
the effects of KKT. First, posttreatment with KKT reverses the progression of tau phosphorylation; 
however, posttreatment with KPL has no effect on tau phosphorylation (Figure 2). Second, 
posttreatment with KKT restores atrophied axons, whereas KPL does not (Figure 3(b)). Third, KKT 
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enhances the activity of PP2A (Figure 4) but is not involved in the regulation of GSK-3β activity 
(Figure 5). 
Recent reports of therapeutic strategies targeting Aβ, such as solanezumab and semagacestat, 
demonstrate that decreasing Aβ deposits or plasma Aβ levels after the appearance of symptoms does 
not improve cognitive dysfunction [6, 27]. In contrast, several reports have shown that tau is 
essential for Aβ-induced neuronal dysfunction in vitro and in vivo [28, 29]. Therefore, a decrease in 
tau phosphorylation may improve the symptoms of AD. From this point of view, it is very interesting 
that KKT reverses the progression of tau phosphorylation and axonal atrophy. 
Our data suggest that KKT decreases the phosphorylation of tau through the activation of PP2A; 
however, the mechanism by which KKT increases PP2A activity remains unknown. The PP2A 
subtype accounts for more than 70% of all phosphatases in the human brain. In addition, the activity 
of PP2A decreases more than that of other phosphatases in the brains of AD patients [30]. Thus, 
PP2A likely plays a critical role in the dephosphorylation of tau. There are reports showing that 
PP2A activators decrease the phosphorylation of tau and reverse memory deficits in an AD model. 
For example, memantine enhances PP2A activity indirectly, and 1 year of treatment with memantine 
significantly decreases the levels of phosphorylated tau in the CSF of AD patients [31, 32]. Other 
reports have shown that sodium selenite, which induces dephosphorylation of tau via PP2A 
activation, improves memory deficits in tau transgenic mice [33]. Therefore, activation of PP2A 
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likely plays an important role in the effects of KKT for AD treatment. However it has also been 
reported that KKT ameliorates scopolamine-induced spatial memory deficits and 
methyl-β-carboline-3-carboxylate(β-CCM)-induced-anxiogenic behavior [34, 35]. These reports 
suggest that KKT may stimulate the cholinergic system and antagonize the benzodiazepine receptor 
system. Multiple constituents of KKT may therefore contribute to its pharmacological effects. 
Our present data indicating that KKT is effective even after Aβ-induced degeneration has occurred 
are important. Future studies should clarify which compounds in KKT are related to the restorative 
effect. KKT extract contains many constituents. Among them, at least ginsenoside Rg1, ginsenoside 
Rb1, saikosaponin a, saikosaponin b1, saikosaponin b2, geniposide, liquiritin, apioliquiritin, 
glycyrrhizic acid, 6-gingerol, and ligustilide were identified in our previous report [7]. Ginsenoside 
Rb1, a constituent in Ginseng Radix, attenuated spatial memory deficits in Aβ (25–35)-injected mice 
[36] and extended axons under Aβ (25–35) treatment (our unpublished data). Therefore ginsenoside 
Rb1 may be one of the active constituents in KKT. 
Also we previously showed that posttreatment with Polygalae Radix extract reversed Aβ 
(25–35)-induced axonal atrophy [37]; therefore, Polygalae Radix may be at least partially 
responsible for the effect of KKT. 
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Chapter 2  
A cross-country comparison of kamikihito toward the development of a global study 
 
2.1  Introduction 
Traditional medicine has been used in East Asia (China, Korea and Japan) to treat various 
symptoms since antiquity. These traditional medicines originated in China 3,000 years ago and were 
introduced to Korea and Japan in the 6th century [38, 39]. Until recently, traditional medicine has 
evolved independently in each country; therefore, slight differences exist in the diagnostic methods 
and symptoms targeted even when traditional formulations with the same origin are used. Recently, 
traditional medicine has been made available to treat intractable diseases in Western medicine, such 
as dementia [40]. However, little evidence regarding the efficacy of this treatment exists because of 
the small number of cases, non-randomized controlled research trial designs and insufficient 
mechanistic explanations [41]. To increase the evidence in favor of traditional medicines, expanded 
cross-country clinical studies are necessary. Clinical study approaches are also useful for evaluating 
the differences between ethnic groups and traditional medical systems. Ideally, researchers across 
countries should be able to use unified formulations of traditional medicine; however, this practice is 
difficult.  
If the same-origin formulations used in each country have equivalent effects, cross-country 
clinical studies can be easily conducted, even when a unified formulation is not available. Moreover, 
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the results can be understood across different countries. However, no comparative studies have 
examined the same-origin but non-identical formulations used in different countries.  
We previously reported the effects of kamikihito (Japanese name, KKT) in a 5XFAD mouse 
model of Alzheimer’s disease [7]. The KKT formulations that have the same origin and components 
are also used in traditional Chinese and Korean medicine (called jia-wei-gui-pi-tang, JGT and 
kami-guibi-tang, KGT, respectively) to treat insomnia, loss of appetite, amnesia, and depression. 
Using Chinese characters, KKT, JGT, and KGT are written similarly in Japanese, Chinese, and 
Korean. To confirm and expand the global usefulness of the formulations, it is important to 
investigate whether these formulations yield equivalent effects. Thus, this study compared the effects 
of KKT and KGT preparations on memory function in normal mice. We prepared three types of 
formulations and investigated the effects of KKT on normal memory [42]. One form of KKT is 
commercially available from a Japanese pharmaceutical company (Kracie), a second form of KKT is 
prescribed as a decoction at Toyama University Hospital, and the final form of KGT is used at the 
Kyung Hee Korean Medical Hospital of Kyung Hee University in Korea.   
       
2.2 Materials and Methods  
All experiments were performed in accordance with the Guidelines for the Care and Use of 
Laboratory Animals of the University of Toyama. 
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2.2.1  Preparation of KKT and KGT extracts 
KKT and KGT are composed of 14 crude drugs. The original plant sources of these drugs and the 
daily human doses administered are shown in Table 1. All crude drugs used for KKT at Toyama 
University Hospital (KKT-TU) were purchased from Tochimoto Tenkaido (Osaka, Japan). The 
mixture of crude drugs (3.3 - fold the daily dose; 100 g) was extracted with 500 ml of water at 100°C 
for 50 min, evaporated under reduced pressure, and freeze-dried to obtain a powder extract (12.3 g, 
yield 12.3%).  
For the KGT at Kyung Hee University (KGT-KHU), all crude drugs were obtained from the 
Kyung Hee Herb Pharmacy (Wonju, Kangwon, Korea) and E-dam Oriental Medicine Materials 
(Namyangju, Gyeonggi, Korea). The mixture of crude drugs (160 - fold the daily dose, 4,720 g) was 
extracted with 80 L of water at 100°C for 3 h. The decoction was filtered, lyophilized, and stored at 
4°C. Ultimately, 760 g of water-extracted powder was obtained using wet granulation (yield 16.1%), 
and 40 g of polyvinylpyrrolidone was added to the extract as an excipient.   
The Kracie KKT (KKT-Kra) was obtained from Kracie Pharma, Ltd. (Tokyo, Japan). All crude 
drugs used for the extract were self-prepared under quality control. The mixture of crude drugs (29.5 
g daily dose) was extracted with 300 ml of water at 100°C for 60 min, evaporated under reduced 
pressure, and spray-dried to obtain a powder extract (5.6 g, yield 19.0%).  
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2.2.2  Preparation of anchusan (AS) 
AS is composed of 7 crude drugs. The original plant sources of these drugs and the daily human 
doses administered are shown in Table 2. For the AS used at the Toyama University Hospital, all 
crude drugs were purchased from Tochimoto Tenkaido. The mixture of crude drugs (5.0 - fold the 
daily dose, 100 g) was extracted with 500 ml of water at 100°C for 50 min, evaporated under 
reduced pressure, and freeze-dried to obtain a powder extract (7.41 g, yield 7.41%).  
 
2.2.3  Animals 
Six-week-old male ddY mice (Japan SLC, Shizuoka, Japan) were housed in groups with free 
access to food and water and maintained in a controlled environment (22 ± 2°C, 50 ± 5% humidity, 
and a 12-h light/dark cycle starting at 7:00 a.m.). Each KKT, KGT, or AS dose was dissolved in 
distilled physiological saline. KKT-TU (500 mg extract/kg/day), KKT-Kra (500 mg extract/kg/day), 
KGT-KHU (500 mg extract/kg/day), AS (500 mg/kg/day), or a vehicle solution (physiological 
saline) was administered orally once daily for 13 days. Open field tests for locomotion were 
performed on Day 7. A novel object recognition test was conducted on Day 8, and an object location 
test was performed on Day 11 (see Fig. 1A). All tests were performed in the daytime and under the 
same illuminated conditions (90 lux). 
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2.2.4  Open field test 
The mice were released for 10 min in a square field (30 × 41 cm; height, 36.5 cm), and a digital 
camera tracked their paths. The distance over which the mice traveled for 10 min (i.e., locomotion 
activity) was analyzed using EthoVision 3.0 (Noldus, Wageningen, Netherlands). This testing was 
conducted in a dimly illuminated room.  
 
2.2.5  Object recognition test 
Two identical objects (ceramic black cat ornaments) were placed at a fixed distance within the 
square field (30 × 41 cm; height, 36.5 cm). A mouse was then placed in the center of the field, and 
the number of times it contacted the two objects was recorded over a 10-min period (training 
session). The mice were then returned to the same field 48 h after the training session, and one of the 
familiar objects used during the training session was replaced with a novel object (a ceramic yellow 
duck ornament). The mice were allowed to explore freely for 10 min, and the number of times that 
they made contact with each object was recorded (test session). A preference index (i.e., the ratio of 
the number of times that a mouse contacted any objects during the training session or the novel 
object during the test session to the number of times that the mice contacted both objects) was used 
as a measure of objective cognitive function. The interval time 48 h was determined by our 
experiments as duration when normal mice cannot keep the memory. 
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2.2.6  Object location test 
 The object location test began the day after the object recognition test. In the training session, 
two identical novel objects (ceramic green frog ornaments) were placed at a fixed distance within the 
open field box. Inside the box, different wall covering patterns were used; one side of the black wall 
had vertical white strips, and the opposite side of the wall had white circles. The two objects were 
placed on the floor of the box. A mouse was placed at the opposite end of the field, and the number 
of explorations of each object was recorded over a 10-min period (training session). After a 48-h 
interval, the test session was conducted during which one of the objects was moved to a different 
position in the field. The mice were allowed to explore freely for 10 min, and the number of 
explorations of each object was recorded (test session). A preference index (i.e., the ratio of the 
number of times that a mouse contacted any object during the training session or the object at the 
novel location during the test session to the number of times that the mouse contacted both objects) 
was used as a measure of spatial memory. 
 
2.2.7 Three-dimensional high-performance liquid chromatography (3D-HPLC) analysis of 
extracts 
Each extract solution (10 mg/ml) was filtered through membrane filter (0.22 µm) and then 
submitted for HPLC analysis (20 µl). The HPLC apparatus (Hitachi Ltd., Japan) consisted of a pump 
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(L-2130) with analysis system software (Elite LaChrom); it was equipped with a photodiode array 
detector (UV 230-400 nm, L-2455), a system controller, an auto injector (L-2200), and a column 
oven (L-2300). The HPLC conditions were as follows: column, LaChrom Ultra C18 (5 µm, Lot No. 
21D5-011; Hitachi Ltd., Japan) with 150 × 4.6 mm I.D.; elutant, (A) H2O containing 0.1% formic 
acid and (B) CH3CN containing 0.1% formic acid (a linear gradient was used from “95% A and 5% 
B” to “30% A and 70% B” for 90 min); temperature, 20°C; and flow rate, 0.2 ml/min. 
 
2.2.8  Statistical Analysis 
Statistical comparisons were performed using a one-way ANOVA followed by a Dunnett's post 
hoc test or a paired t-test using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). Values 
of p < 0.05 were considered significant. The mean data values are presented together with their 
associated standard errors (SE). 
 
2.3  Results 
 
2.3.1  KKT and KGT enhance object recognition and location memory in ddY mice 
To investigate the effects of each drug on object recognition and location memory, KGT-KHU 
(500 mg/kg/day), KKT-TU (500 mg/kg/day), KKT-Kra (500 mg/kg/day), AS (500 mg/kg/day), or a 
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vehicle solution was orally administered once daily for 13 days. On the 7th day of administration, an 
open field test was performed. The locomotor activity was similar across all groups (p > 0.05, 
one-way ANOVA followed by Dunnett's post hoc test, Figure 6B). The novel object recognition test 
was performed on the 8th day, and the object location test began on the 11th day. In this experiment, 
AS was used as a reference drug because its components do not overlap with KKT-TU, KGT-KHU, 
or KKT-Kra (except for Glycyrrhizae Radix). AS is used clinically to treat stomachaches and loss of 
appetite. 
In the novel object recognition test, the vehicle- and AS-treated mice showed equivalent 
exploratory behaviors that were close to chance (50%) in the test session (p > 0.05, paired t-test). 
This finding indicates that the vehicle- and AS-treated mice were unable to maintain memories of the 
objects presented in the training session. In contrast, the KGT-KHU- and KKT-Kra-treated mice 
showed significant exploratory behaviors in the presence of a novel object in the test session (p = 
0.015 and 0.014, paired t-test). The KKT-TU-treated mice also showed above-chance exploratory 
behaviors; however, this result was not significant (p = 0.079, paired t-test, Fig. 7A).  
In the object location test, the vehicle- and AS-treated mice showed similar exploratory behaviors 
that approximated chance (50%) in the test session (p > 0.05, paired t-test), which indicated that 
these mice were unable to maintain the spatial memories acquired during the training session. In 
contrast, KGT-KHU- (p = 0.047), KKT-TU- (p = 0.003), and KKT-Kra-treated (p = 0.001) mice 
32 
 
showed significant exploratory behaviors towards novel objects (paired t-test, Fig. 7B). These results 
suggest that KKT and KGT have similar effects on normal memory enhancement.  
 
2.3.2  3D HPLC analysis 
The 3D-HPLC profiles of each preparation are shown in Figure 8A. The compound distributions 
with UV absorbance were plotted by the retention time (x-axis), wavelength (y-axis) and content 
(color bar). The general profiles of KKT-TU, KGT-KHU, and KKT-Kra were similar, but there were 
several differences in the peak height. In contrast, the peak profiles of AS were quite different from 
KKT and KGT.  
In the chromatograms at 260 nm (Figure 8B) and 310 nm (Figure 8C), some main compounds 
were annotated. Geniposide derived from Gardeniae Fructus was present at slightly higher levels in 
KKT-TU compared with KGT-KHU and KKT-Kra. 
6'-O-[6-O-(4-Hydroxy-Z-cinnamoyl-β-D-glucopyranosyl]geniposidic acid methyl ester derived from 
Gardeniae Fructus was present at comparatively low levels in KGT-KHU. The glycyrrhizin and 
liquiritin derived from Glycyrrhihizae Radix were present at high levels in KKT-Kra.  
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Table 1  Compositions of kamikihito and kami-guibi-tang 
Crude drug name Original plant source Kyung HeeUniversity
University of
Toyama Kracie
(g/day) (g/day) (g/day)
Ginseng Radix Panax ginseng 3 3 3
Atratylodis Rhizoma Atratylodes japonica 3 3 3
Poria Poria cocos 3 3 3
Bupleuri Radix Bupleurum falcatum 3 3 3
Zizyphi Spinosi Semen Ziziphus jujuba var. spinosa 3 3 3
Longan Arillus Euphoria longana 3 3 3
Astragali Radix Astragalus membranaceus 2 2 2
Angelicae Radix Angelica acutiloba 2 2 2
Gardeniae Fructus Gardenia jasminoides 2 3 2
Polygalae Radix Polygala tenuifolia 1.5 1.5 1.5
Zizyphi Fructus Ziziphus jujuba var. inermis 1.5 1.5 1.5
Glycyrrhizae Radix Glycyrrhiza uralensis 1 1 1
Saussureae Radix Saussurea lappa 1 1 1
Zingiberis Rhizoma Zingiber officinale 0.5 1 0.5
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Table 2   Composition of anchusan 
 
Crude drug name Original plant source University of
Toyama
(g/day)
Cinnamomi Cortex Cinnamomum cassia 4
Corydalis Tuber Corydalis turtschaninovii 4
Ostreae Testa Ostrea gigas 4
Foeniculi Fructus Foeniculum vulgare 4
Glycyrrhizae Radix Glycyrrhiza uralensis 1.5
Amomi Semen Amomum xanthioides 1.5
Alpiniae officinari Rhizoma Alpinia officinarum 0.7
 
 
  
 
Figure 6. Experimental schedule and locomotion.
(A) The experimental schedule for locomotion, object recognition and object location tests. (B) 
KGT-
mg/kg/day), or vehicle solutions were administered daily to ddY mice for 13 days. On the 7th day of 
administration, open field tests were performed. The total distances traveled for 10 min in an open 
field are s
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Figure 7. The effects of KKT, KGT, and AS on object recognition and location memories. 
KGT-
mg/kg/day), or v
object recognition test was performed on the 8th day. Preferential indices are shown. The white 
columns show the results of the training session, and the black columns show the 
session. B) The object location test was performed on the 11th day. Preferential indices are shown. 
The white columns show the results of the training session, and the black columns show the results 
of the test session. * 
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2.4  Discussion 
Although the prescribed original plant sources were the same across three formulations, the crude 
drugs used for each type of formulations were obtained from different places. In addition, the 
preparation methods for each extracted drug were slightly different. The 3D-HPLC profiles of 
KGT-KHU, KKT-TU, and KKT-Kra showed a similar distribution of peaks but slight differences in 
the amount of compounds present. However, all three formulations yielded enhancements in object 
and spatial memory in normal mice; this finding suggests that KKT formulations prepared in 
different countries have equivalent effects even if the amounts of constituents are not strictly 
identical.  
This is the first report to show that KKT and KGT are memory stimulants. KGT may also be 
useful to treat dementia because we previously reported that KKT improved memory dysfunction in 
the 5XFAD mouse model of Alzheimer’s disease [7].   
KKT and KGT formulations produced memory enhancement effects attributed to drug-specific 
components because AS had no effect memory enhancement in normal mice. The components of AS 
do not overlap with KKT and KGT (except for Glycyrrhizae Radix), and the AS compounds peaks 
were quite different from the other drugs. In our previous study, Ginseng Radix, Polygalae Radix, 
and Astragali Radix produced axonal extension effects in cultured neurons and the mouse brain [35, 
43, 44]. We also indicated that axonal growth in the brain of normal mice is involved in memory 
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enhancement [45]. Some of constituents in Gardeniae Fructus including geniposide have neurite 
outgrowth activity [46]. In addition, Huang et al. reported that tenuigenin, an active compound of 
Polygalae Radix, enhanced learning and memory in normal mice [47]. These data suggest that the 
active crude drug in KKT for memory enhancement might not be specified so easily. However, it is 
important to determine which compounds in these drugs contribute to the memory enhancement 
effects. As shown in Figure 8A, a thousand compounds are contained in KKT and KGT. Analyzing 
the pharmacological activities and underlying mechanisms of each compound one by one is very 
inefficient, and the sum of each event detected in a mono-crude drug treatment does not necessary 
indicate a net effect of a particular formulation. Therefore, we are identifying the main signaling 
pathway of KKT, which is crucially related to memory enhancement, as an important first step. If we 
can identify the main signaling pathway for the memory enhancements of KKT, the active 
constituents that contribute to the pathway could be focused on more easily.    
Yokukansan (called yokukansan in Japan, yi-gan san in China, and ukgansan in Korea) is a 
traditional herbal medicine that has been used to treat restlessness, insomnia and agitation. Iwasaki et 
al. reported that yokukansan improved the behavioral and psychological symptoms of dementia 
(BPSD) in a clinical study performed in Japan [48]. Additional clinical and basic studies have been 
conducted, and the evidence for yokukansan with regard to BPSD has grown [49]. However, the 
expansion of these studies has been limited to Japan; specifically, 22 clinical and 39 basic studies 
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that involved yokukansan have been conducted in Japan. In contrast, only one ukgansan study was 
reported in Korea that showed neuroprotective effects on MPP+/MPTP-induced cytotoxicity [50]. A 
global clinical study of yokukansan has not been performed to date, and the cross-country, reliable 
effectiveness of yokukansan is not understood. To address this problem, global clinical studies must 
be conducted.  
In this study, same-origin traditional formulations, which were prepared differently in Japan and 
Korea, showed equivalent effects in in vivo experiments. The 3D-HPLC data showed that most 
major components in KKT were also present in KGT, but with slight differences. These results 
suggest that the use of identical formulations is not required for investigating the pharmacological 
effects of traditional formulations in cross-country clinical studies. These types of studies may 
expand the usefulness of traditional medicine for the clinical study of dementia in different countries. 
Moreover, this study is the first to examine KKT and KGT and may support the progression to 
global clinical studies.     
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Conclusions 
Results in chapter 1 demonstrated that KKT dephosphorylated tau via PP2A activation and 
improved axonal atrophy, even after those Aβ-induced deteriorative phenomena already occurred 
[15]. In chapter 2, the effects of KKT used in Japan and Korea were compared and both of them 
showed normal memory enhancement effects equivalently [42].  
Previous our basic research and other clinical study demonstrated that KKT improved the 
cognitive disorder in AD [7, 51], suggesting that KKT might be effective after onset of AD. We 
suppose such a therapeutic effect of KKT on AD may be brought at least by PP2A activation.  
However, the mechanism of KKT leading to regulation of PP2A remains unknown. To investigate 
the signal pathway of KKT, we have tried to identify the most upstream molecule in KKT-triggered 
signaling [52].         
KKT enhanced the cognitive function in the normal situation, suggesting that effects of KKT are 
not necessary limited to repairing Aβ-induced damages. Up regulation of basic neuronal activity is 
doable by KKT treatment. Therefore, KKT might be also applicable to other dementia states such as 
aging-associated cognitive decline. 
Future studies to clarify the whole underlying mechanisms of KKT against cognitive disorder and 
to confirm effects of KKT on AD or other type of dementia clinically may pave the way for 
overcoming dementia.  
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